Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 8/20 | 0.44 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | CA4 | P22748 | 8/20 | 0.44 |
| ▸ | CA9 | Q16790 | 8/20 | 0.44 |
| ▸ | ESRRA | P11474 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18128900 | 0.87 | KCNMA1 (0.56) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL18128901 | 0.86 | KCNMA1 (0.71) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL18128897 | 0.79 | KCNMA1 (0.47) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL18128905 | 0.79 | KCNMA1 (0.53) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL2820052 | 0.78 | KCNMA1 (0.53) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL18128898 | 0.77 | CA1 (0.60) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL18128903 | 0.75 | CA1 (0.60) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL16118277 | 0.71 | KCNMA1 (0.73) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL16118288 | 0.71 | KCNMA1 (0.81) | KCNMA1CA1CA2CA4CA9 | |
| SCHEMBL16118314 | 0.71 | KCNMA1 (1.00) | KCNMA1CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701646-B2 | Small molecule inhibitors of PI3-kinase signaling | TUFTS UNIVERSITY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160297777-A1 | SMALL MOLECULE INHIBITORS OF PI3-KINASE SIGNALING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297777-A1 | SMALL MOLECULE INHIBITORS OF PI3-KINASE SIGNALING | PIK3R5, PIK3R3, PIK3R4 | KCNMA1 1031/4885CA1 3696/4885CA2 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.